Please login to the form below

Not currently logged in
Email:
Password:

chronic heart failure

This page shows the latest chronic heart failure news and features for those working in and with pharma, biotech and healthcare.

Vas Narasimhan takes top Novartis job on Jimenez departure

Vas Narasimhan takes top Novartis job on Jimenez departure

showed an uptick in performance but remains under strategic review - and disappointing take-up of new chronic heart failure drug Entresto (sacubitril/valsartan).

Latest news

  • Vifor wins European approval for Veltassa Vifor wins European approval for Veltassa

    therapy due to heart failure and/or chronic kidney disease. ... RAAS inhibitors can also lead to elevated potassium levels, which can lead to organ failure, however researchers have found patiromer can reduce potassium levels.

  • CV data sets up Novartis' Ilaris for blockbuster sales CV data sets up Novartis' Ilaris for blockbuster sales

    with a prior heart attack and inflammatory atherosclerosis when added to standard therapy. ... chronic heart failure therapy Entresto (sacubitril/valsartan) - also predicted to become a blockbuster but currently growing slowly thanks largely to payer

  • What future for serelaxin after phase III miss? What future for serelaxin after phase III miss?

    What future for serelaxin after phase III miss? Novartis' acute heart failure therapy misses two main endpoints. ... credibility". Novartis had been hoping to build a valuable heart failure franchise around serelaxin for AHF and Entresto (sacubitril and

  • FDA turns down AZ's ZS-9 once again on manufacturing issues FDA turns down AZ's ZS-9 once again on manufacturing issues

    Elevated serum potassium is associated with multiple diseases - including chronic heart failure (CHF) and chronic kidney disease (CKD) - and can lead to potentially fatal abnormal heart rhythms.

  • AZ nears EU approval for hyperkalaemia drug Lokelma AZ nears EU approval for hyperkalaemia drug Lokelma

    Hyperkalaemia is commonly associated with chronic heart failure and chronic kidney disease, and carries risk of potentially fatal cardiac arrhythmias.

More from news
Approximately 4 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • A healthy challenge A healthy challenge

    Chronic diseases. One of the standout findings of the Health at a Glance report concerned the impact of chronic diseases in Europe. ... All told, 50 million people in the EU are afflicted by conditions such as diabetes, congestive heart failure, chronic

  • Pharma deals during July 2013 Pharma deals during July 2013

    Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates. ... Omecamtiv mecarbil is currently in phase II trials

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Enablers of drug innovation could lie in the numbers

    As drugs become more and more targeted, the need for this data is compounded, and information such as the whereabouts of the greatest concentration of patients with chronic heart failure, and ... a reduced ejection fraction within the New York Heart

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics